Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure

Heart

Volumn 97, Issue 14, 2011, Pages 1158-1163

  Rychli, Kathrin ^a   Richter, Bernhard ^a   Hohensinner, Philipp J ^a   Ali, Kariem Mahdy ^a   Neuhold, Stephanie ^a   Zorn, Gerlinde ^a   Berger, Rudolf ^a   Mörtl, Deddo ^a   Huber, Kurt ^b   Pacher, Richard ^a   Wojta, Johann ^a   Niessner, Alexander ^a   Hülsmann, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SCATTER FACTOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; AUSTRIA; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEPATOCYTE GROWTH FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 79959358942     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.220228     Document Type: Article

References (30)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
2. Pascual-Figal DA, Domingo M, Casas T, et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008;29:1011-18. (Pubitemid 351844674)
3. Beohar N, Rapp J, Pandya S, et al. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol 2010;56:1287-97.
4. Li Y, Takemura G, Kosai K, et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003;107:2499-506. (Pubitemid 36605235)
5. Jayasankar V, Woo YJ, Bish LT, et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003;108(Suppl 1):II230-6.
6. Jin H, Wyss JM, Yang R, et al. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr Pharm Des 2004;10:2525-33. (Pubitemid 38997432)
7. Chin BS, Chung NA, Gibbs CR, et al. Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. Am J Cardiol 2002;90:1258-60. (Pubitemid 35346888)
8. Ueno S, Ikeda U, Hojo Y, et al. Serum hepatocyte growth factor levels are increased in patients with congestive heart failure. J Card Fail 2001;7:329-34. (Pubitemid 34008164)
9. Zhu Y, Hojo Y, Ikeda U, et al. Production of hepatocyte growth factor during acute myocardial infarction. Heart 2000;83:450-5. (Pubitemid 30316765)
10. Wang W, Yang ZJ, Ma DC, et al. Induction of collateral artery growth and improvement of post-infarct heart function by hepatocyte growth factor gene transfer. Acta Pharmacol Sin 2006;27:555-60.
11. Lamblin N, Susen S, Dagorn J, et al. Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J 2005;150:137-43. (Pubitemid 41097441)
12. Niessner A, Hohensinner PJ, Rychli K, et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009;30:789-96.
13. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999;20:683-93. (Pubitemid 29204354)
14. Katoh H, Shimada T, Inoue S, et al. Reduced high serum hepatocyte growth factor levels after successful cardioversion in patients with atrial fibrillation. Clin Exp Pharmacol Physiol 2004;31:145-51. (Pubitemid 38338710)
15. Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000;102:246-52. (Pubitemid 30451784)
16. Yasuda S, Goto Y, Sumida H, et al. Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure. Hypertension 1999;33:1374-8. (Pubitemid 29282657)
17. Hu ZP, Wang BN, Qian HY, et al. Fixed-dose telmisartan/ hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in decreasing serum hepatocyte growth factor and improving endothelial dysfunction in hypertensive patients. Int Heart J 2010;51:252-8.
18. Tamura M, Arakaki N, Tsubouchi H, et al. Enhancement of human hepatocyte growth factor production by interleukin-1 alpha and -1 beta and tumor necrosis factor-alpha by fibroblasts in culture. J Biol Chem 1993;268:8140-5. (Pubitemid 23120397)
19. Kataoka H, Kawaguchi M. Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. FEBS J 2010;277:2230-7.
20. Broten J, Michalopoulos G, Petersen B, et al. Adrenergic stimulation of hepatocyte growth factor expression. Biochem Biophys Res Commun 1999;262:76-9. (Pubitemid 29412626)
21. Yang Z, Wang W, Ma D, et al. Recruitment of stem cells by hepatocyte growth factor via intracoronary gene transfection in the postinfarction heart failure. Sci China C Life Sci 2007;50:748-52. (Pubitemid 50000366)
22. Zhou YJ, Yang HW, Wang XG, et al. Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells. Life Sci 2009;85:670-7.
23. Chowdhury M, Ghosh J, Slevin M, et al. A comparative study of carotid atherosclerotic plaque microvessel density and angiogenic growth factor expression in symptomatic versus asymptomatic patients. Eur J Vasc Endovasc Surg 2010;39:388-95.
24. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68. (Pubitemid 50011582)
25. Xu-Cai YO, Wu Q. Molecular forms of natriuretic peptides in heart failure and their implications. Heart 2010;96:419-24.
26. Chen HH, Martin FL, Gibbons RJ, et al. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart 2009;95:1315-19.
27. Rychli K, Niessner A, Hohensinner PJ, et al. Prognostic value of pigment epithelium-derived factor in patients with advanced heart failure. Chest 2010;138:656-64.
28. Anker SD, Coats AJ. Metabolic, functional, and haemodynamic staging for CHF? Lancet 1996;348:1530-1.
29. Hohensinner PJ, Rychli K, Zorn G, et al. Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost 2010;103:435-41.
30. Richter B, Rychli K, Hohensinner PJ, et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 2010;213:545-8.